Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease-Reference-Cited by-同舟云学术

Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease

Published:2021-05-03 Issue:1S Volume:33 Page:e574-e579
ISSN:0954-691X
Container-title:European Journal of Gastroenterology & Hepatology
language:en
Short-container-title:

Author:

Innocenti Tommaso,Roselli Jenny,Lynch Erica N.,Apolito Pasquale,Parisio Laura,Bagnoli Siro,Macrì Giuseppe,Rogai Francesca,Tarocchi Mirko,Milani Stefano,Galli Andrea,Milla Monica,Dragoni Gabriele

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Reference38 articles.

1. Ulcerative colitis.;Ungaro;Lancet,2017

2. Crohn’s disease.;Torres;Lancet,2017

3. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.;Amiot;Therap Adv Gastroenterol,2015

4. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.;Soler;J Pharmacol Exp Ther,2009

5. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.;Hesterberg;Gastroenterology,1996

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers;American Journal of Gastroenterology;2024-07-12

2. IFNγ induces epithelial reprogramming driving CXCL11-mediated T cell migration;2024-02-07

3. Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications;Inflammatory Bowel Diseases;2023-05-26

4. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis;Clinical Gastroenterology and Hepatology;2023-04

5. Ustekinumab/vedolizumab;Reactions Weekly;2022-06